Evidence map›Paper›PMID 34165261›Full record

ArticleCancer medicine2021

Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer.

Jinlong Cao, Jianpeng Li, Xin Yang, Pan Li, Zhiqiang Yao, Dali Han, Lijun Ying, Lijie Wang, Junqiang Tian

Abstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jinlong CaoDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, People's Republic of China.ORCID 0000-0002-6703-8949
Jianpeng LiDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, People's Republic of China.ORCID 0000-0002-0660-7802
Xin YangReproductive Medicine Center, The Second Hospital of Lanzhou University, Lanzhou, People's Republic of China.
Pan LiDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, People's Republic of China.
Zhiqiang YaoDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, People's Republic of China.ORCID 0000-0002-4633-7624
Dali HanDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, People's Republic of China.
Lijun YingDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, People's Republic of China.
Lijie WangDepartment of Gynecology, The Second Hospital of Lanzhou University, Lanzhou, People's Republic of China.
Junqiang TianDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, People's Republic of China.ORCID 0000-0002-4529-4650

Funding

Cuiying Graduate Supervisor Applicant Training Program of Lanzhou University Second Hospital 201704Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital CY2017-BJ16Doctoral Research Foundation of Lanzhou University Second Hospital ynbskyjj2015-2-7Industry Planning Project of Health Department of Gansu Province GWGL2013-30Science and Technology Project of Chengguan District, Lanzhou City, Gansu Province Science and Technology Bureau 2017KJGG0052the Fundamental Research Funds for the Central Universities 561219007
6 · The paper itself

Abstract

The emergence of immunotherapy has provided an option of treatment methods for bladder cancer (BC). However, the beneficiaries of immunotherapy are still limited to small-scale patients, and immunotherapy-related adverse events often occur. It is a major challenge for clinical work to study the immune subtypes of BC and the molecular mechanism of immune escape, and identify the immune responders accurately. Here, we explore the immune molecular subtypes of bladder cancer and potential escape mechanisms. First, we screened the expression profiles of 303 differentially expressed immune-related genes in BC patients from the Cancer Genome Atlas (TCGA) database, and successfully identified 4 molecular subtypes of BC. By comparing the clinical characteristics, immune cells infiltration, the expression of checkpoint genes, human leukocyte antigen (HLA) genes, and gene mutation status of different subtypes, we identified different clinical and immunological characteristics of 4 subtypes. Among 4 subtypes, Cluster 2 met the general characteristics of immunotherapy responders and responded well to immunotherapy, while Cluster 4 had the highest expression of immune characteristics, and is similar to the immune environment of normal bladder tissue. Then, the weighted gene co-expression network analysis (WGCNA) of immune-related genes revealed that brown module was positively correlated with subtypes. Pathway enrichment analysis explored the major pathways associated with subtypes, which are also associated with immune escape mechanisms. Moreover, the decision tree model, which was constructed by the principle of random forest screening factors, was also validated in internal validation set and external validation set from the Gene Expression Omnibus (GEO) cohort (GSE133624), and could achieve accurate subtypes prediction for BC patients with high-throughput sequencing. Taken together, we explored the immune molecular subtypes and their mechanisms of BC, and these results may provide guidance for the development of new BC immunotherapy strategies.

Indexed as

ImmunotherapyDatabases, GeneticDecision TreesGene Expression ProfilingGenes, cdcHLA AntigensHumansImmunity, CellularMutationReproducibility of ResultsTreatment OutcomeTumor EscapeUrinary BladderUrinary Bladder NeoplasmsHLA Antigensdecision tree modelimmune molecular subtypesimmunotherapyrandom forestthe cancer genome atlas

Identifiers

PMID34165261
PMCPMC8335815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.